Nelfinavir - PharmaKB

Viracept(nelfinavir)

Viracept (nelfinavir) is a small molecule pharmaceutical. Nelfinavir was first approved as Viracept on 1997-03-14. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
urogenital diseases	D000091642
immune system diseases	D007154

Trade Name

FDA

EMA

Viracept (discontinued: Viracept)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Nelfinavir mesylate

Tradename	Company	Number	Date	Products
VIRACEPT	Agouron Pharmaceuticals	N-020779 RX	1997-03-14	1 products, RLD, RS
VIRACEPT	Agouron Pharmaceuticals	N-021503 RX	2003-04-30	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
viracept	New Drug Application	2024-03-22

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
acquired immunodeficiency syndrome	EFO_0000765	D000163	B20

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J05: Antivirals for systemic use

— J05A: Direct acting antivirals

— J05AE: Protease inhibitors, direct acting antivirals

— J05AE04: Nelfinavir

HCPCS

No data

Clinical

Clinical Trials

147 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	1	9	1	1	4	16

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	—	3	—	—	2	5
Communicable diseases	D003141	—	—	—	1	—	—	1	2
Hiv seropositivity	D006679	—	—	—	1	—	—	—	1
Sarcoma	D012509	—	—	—	1	—	—	—	1
Kaposi sarcoma	D012514	—	C46	—	1	—	—	—	1
Mycobacterium avium-intracellulare infection	D015270	EFO_0007386	—	—	1	—	—	—	1
Mycobacterium infections	D009164	—	A31.9	—	1	—	—	—	1
Opportunistic infections	D009894	—	—	—	1	—	—	—	1
Cytomegalovirus retinitis	D017726	EFO_1001302	—	—	1	—	—	—	1
Retinitis	D012173	—	H30.9	—	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Nelfinavir
INN	nelfinavir
Description	Nelfinavir is an aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. It has a role as a HIV protease inhibitor and an antineoplastic agent. It is a member of benzamides, a member of phenols, an aryl sulfide, a secondary alcohol, a tertiary amino compound and an organic heterobicyclic compound. It is a conjugate base of a nelfinavir(1+).
Classification	Small molecule
Drug class	antivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C